Drugs / Masupirdine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05397639 | Nov 2022 → Dec 2026 expected | Alzheimer disease | Suven Life Sciences Limited | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02580305 Comparator | Sep 2015 → Nov 2019 | Alzheimer disease | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03564964 Background | — | Alzheimer disease | Suven Life Sciences Limited | No longer available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Masupirdine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397639 ↗ |
| Known as | Masupirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4117187 ↗ |
| Known as | SUVN-502 | “A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine...” NCT05397639 ↗ |
| Action | Inhibit | “Serotonin 6 (5-HT6) receptor antagonist” CHEMBL4117187 ↗ |
| Modality | Small molecule | — CHEMBL4117187 ↗ |
| Route | Oral | “Once-daily, tablets, orally” NCT02580305 ↗ |
| Target | HTR6 | “Serotonin 6 (5-HT6) receptor antagonist” CHEMBL4117187 ↗ |